Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 juin 2020 08h15 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
01 juin 2020 07h45 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
08 mai 2020 08h05 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update

Tebipenem HBr Phase 3 trial enrollment complete with top-line data expected in the third quarter of 2020 SPR720 Phase 2a NTM trial initiation planned for the second half of 2020 Conference...
05 mai 2020 16h01 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection

CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
04 mai 2020 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
30 avr. 2020 18h59 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
16 avr. 2020 08h30 HE | Source: Spero Therapeutics, Inc.

Spero Announces Appointment of Scott Jackson to its Board of Directors

CAMBRIDGE, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
31 mars 2020 16h45 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
16 mars 2020 08h45 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update

CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
11 mars 2020 08h30 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection

CAMBRIDGE, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...

Page précédente